Avoid common mistakes on your manuscript.
Correction to: Dermatol Ther (Heidelb) https://doi.org/10.1007/s13555-023-01086-9
The authors would like to share the following corrections to their publication:
The email address of the corresponding author was updated to "andreas.pinter@pinter-med.com”.
On page 1, the words ‘Clinicaltrial.gov identifier’ were removed.
In the Introduction, the word ‘prospective’ was added to describe PSoHO.
In relation to super responders, the word ‘weight’ was removed and the incorrect citations of 13–15 were corrected.
Mastorino L, Susca S, Cariti C, et al. “Superresponders” at biologic treatment for psoriasis: a comparative study among IL17 and Il23 inhibitors. Exp Dermatol. 2022;32:2187–8.
Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, et al. Super-responders in moderate–severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life. 2022;12:1412.
Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. J Eur Acad Dermatol Venereol. 37(10):2016–27.
The layout of Table 1 was updated for clarity and the statistical appendix is now provided.
Outcomes | Definition |
|---|---|
Effectiveness | |
Primary outcome | Patients who achieved (a) At least a 90% improvement in the PASI score (PASI90), or (b) A score of 0 or 1 in sPGA, or (c) Both outcomes |
PASI100 | Patients who achieved 100% improvement in the PASI score |
PASI90 | Patients who achieved at least a 90% improvement in the PASI score |
Quality of life | |
DLQI (0,1) | Patients with an available DLQI score of 2 or greater at baseline and who subsequently achieved a DLQI score of 0 or 1 |
Durability of effectiveness | |
Durability of effectiveness outcome | Patients who met the primary outcome at week 12 and who subsequently at months 6 and 12 achieved an improvement of (a) At least a 75% in PASI score (PASI75), or (b) 2 or more points in sPGA score from baseline, or (c) Both outcomes |
PASI100 durability outcome | Patients who achieved PASI100 at week 12 and then maintained PASI100 at both months 6 and 12 |
PASI90 durability outcome | Patients who achieved PASI90 at week 12 and then maintained at least PASI90 at both months 6 and 12 |
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Pinter, A., Costanzo, A., Khattri, S. et al. Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatol Ther (Heidelb) 14, 1495–1496 (2024). https://doi.org/10.1007/s13555-024-01105-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-024-01105-3